Eurand is a global specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on our proprietary drug formulation technologies. With more than 30 years experience, Eurand is a world leader in drug delivery, offering comprehensive technology platforms designed to optimize the performance of drug substances. Using these technologies Eurand turns difficult drug candidates into easy to administer, successful pharmaceutical products. Our technologies can be applied both to enable the development of new drug entities and as effective life cycle management tools in order to prolong the market life of products. Eurand’s technology platforms include bioavailability enhancement of poorly soluble drugs, customized release and taste-making/fast-dissolving formulations. A fourth technology platform, drug conjugation, is also under development.

Eurand is a global company employing more than 480 employees with facilities in the United States and Europe.  The company was founded in Milan, Italy in 1969.  From 1989-1999, Eurand was part of American Home Products Corporation (now Wyeth). Eurand became independent in 1999 when affiliates of Warburg Pincus LLC and Gearóid Faherty, Eurand’s Chief Executive Officer, acquired the drug delivery business of American Home Products Corporation.  In May 2007, following a successful IPO, Eurand became a public company and is listed on the NASDAQ Exchange in New York under the symbol EURX.

Our business 

Eurand is dedicated to the continued development and commercialization of breakthrough technologies and products that better satisfy patients’ needs. Our research efforts are focused on the development of treatment options with enhanced efficacy, superior safety and convenient dosing.

Our product pipeline consists of products developed internally and ones which are developed with partners on a co-development basis. Currently, our most advanced products include three co-development products and two proprietary product candidates.

ZentaseTM (EUR-1008) is our lead product candidate. Eurand has completed two phase III clinical trials on its lead product candidate Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI) and filed the first segment of its rolling NDA for this product in June 2007. 

We will continue to invest in our extensive research and development capabilities in the US and Europe and continue to seek new product development opportunities. These products may originate from our own research and development laboratories or may be in-licensed from other companies or academic institution.

Our Technology

Eurand’s broad range of technologies offer our partners multiple opportunities for the development of enhanced formulations of their marketed drugs or enable the development of earlier stage drug candidates by improving bioavailability, reducing frequency of administration or aiding convenience.

Eurand’s proprietary drug formulation technologies include four primary technology platforms and nine distinct technologies.

These four primary technology platforms include:

• Customized Release to control the release rate of drugs in the body thereby reducing frequency of administration and potentially enhancing efficacy and tolerability;

• Dosage Form to improve patient compliance through more convenient dosage forms such as orally disintegrating tablets and taste-masked drugs;

• Bioavailability Enhancement to improve absorption of poorly water soluble drugs, resulting in dose reduction and improved onset of action; and

• Drug Conjugation offering the potential to extend drug half-life and to target specific organs or other biological targets such as tumors

Our ability to meet the drug optimization goals of our collaboration partners, coupled with our broad and validated technology platform and multinational research and development infrastructure, has allowed us to attract many of the leading pharmaceutical companies as collaboration partners and licensees. We have had four products approved by the FDA since 2000 and have currently many product candidates in development for ourselves and our partners.  Since January 2005, we have signed 20 new co-development agreements with pharmaceutical companies located in the United States, Europe and Japan.

We have successfully applied our technologies to drug products in a diverse range of therapeutic areas including cardiovascular, gastrointestinal, pain, nutrition and respiratory.

Our Products

Our licensees have commercialized more than 50 products worldwide that utilize our technologies.
These licensees, who include Eisai, GlaxoSmithKline, Novartis and sanofi-aventis, currently market products using our technologies in many of the world's largest pharmaceutical markets

We offer a portfolio of early to late-stage products utilizing our drug delivery technologies:

Zentase is a zero-overfill, highly-stable, porcine-derived pancreatic enzyme product (PEP) for the treatment of EPI.  A potentially lethal disease, EPI can occur as a complication of a variety of diseases, including cystic fibrosis, pancreatic cancer, surgery and chronic pancreatitis. There are no reliable statistics on the worldwide incidence of EPI, but in the U.S., it is estimated that more than 200,000 people suffer from EPI.  Results from two phase III studies of Zentase show a statistically and clinically significant improvement in the absorption of fat, protein and nutrients in patients suffering from EPI. Eurand is seeking licensee for this product in Japan and Europe.

Other products available for out-licensing:

• Diffucaps Cyclobenzaprine ER capsules 15 and 30mg
• Advatab Paracetamol ODT 250 and 500mg
• Advatab Cetirizine ODT 10mg
• Advatab Ranitidine ODT 150mg
• Microcaps Ibuprofen fast melting tablets 200mg
• Alendronate HCl 70 mg Once Weekly tablets
• Diffucaps Pseudoephedrine HCL SR capsules 120mg
• Diffucaps Sodium Diclofenac SR capsules 75 and 150mg
• Diffucaps Vitamin C 300mg – Zinc 5mg
• Diffucaps Vitamin C 500mg
• Diffucaps Diltiazem SR capsules 120-180-240-300 and 360mg (once daily)
• Diffucaps Isosorbide-5-Mononitrate SR capsules 40-50 and 60mg
• Diffucaps Nifedipine SR capsules 30 and 60mg (once daily)

Our objective is to be a leader in the development, manufacturing and commercialization of innovative specialty pharmaceutical products. Our strategy is to use our innovative technologies and know-how to enable the development of novel, value-added products that can improve patient's lives.

Throughout our history, we have invested in the development and application of innovative technologies that have resulted in the commercialization of more than 40 products worldwide. We have gained the insight and understanding of the global healthcare industry to develop products that meet the needs of patients, care providers and payors. We intend to build on those successes and continue to develop products that will help satisfy the unmet medical needs of the future.

We will continue to invest in our extensive research and development capabilities in the US and Europe and continue to seek new product development opportunities. These products may originate from our own research and development laboratories or may be in-licensed from other companies or academic institutions.